irofulven + prednisone

**Irofulven + prednisone** is an investigational combination therapy primarily studied in metastatic castration-resistant prostate cancer (mCRPC), especially in patients who have failed androgen receptor-targeted therapy and/or docetaxel chemotherapy. **Irofulven** is a semisynthetic derivative of illudin S, acting as a DNA alkylating agent and inhibitor, causing cytotoxic DNA damage and cell death, particularly in tumor cells with specific DNA repair deficiencies. **Prednisone** is a synthetic glucocorticoid used as an anti-inflammatory and immunosuppressant; in prostate cancer, it is commonly added to cytotoxic regimens to reduce side effects, manage cancer-related symptoms, and may provide a modest direct antitumor effect. The combination generally involves intravenous irofulven on days 1 and 8 of a 21-day cycle (0.45 mg/kg per dose), with daily oral prednisone (commonly at 10 mg)[1][3][4][5].

Other names

irofulven + prednisolone